Original reporting and analysis on the stories shaping biotech.
Takeda's zasocitinib just posted Phase 3 psoriasis data that crushed its only direct rival and delivered biologic-level skin clearance from a once-daily pill. The $4 billion acquisition is looking very smart right now.
The team behind MyoKardia's $13.1 billion sale to Bristol Myers Squibb just reunited, renamed themselves Kardigan, and raised $400 million in one of 2026's largest biotech IPOs. Three heart disease drugs, zero approved competitors, and a very familiar playbook.
Italy's state lender just helped a family-owned pharma company spend $4.1 billion to buy its way into the U.S. rare disease market. It's one of the most unusual financing structures in recent pharma M&A history, and the stakes are enormous.
Eli Lilly is spending up to $3.8 billion to acquire psychedelics-focused AtaiBeckley, marking the largest Big Pharma bet ever on psychedelic medicine. The deal puts Lilly on a collision course with J&J's $2 billion Spravato franchise and signals that the psychedelics industry just graduated from fringe to pharma mainstream.
For a decade, the most powerful cholesterol drugs required injections, and most eligible patients never used them. Merck's LIPFENDRA just became the first oral PCSK9 inhibitor approved by the FDA, matching injectable-level potency in a once-daily pill at one-third the price.
Novartis's Fabhalta just converted its provisional FDA approval into the real thing, becoming the first complement inhibitor proven to protect kidney function in IgA nephropathy. The two-year data that sealed the deal are worth paying attention to.
For six years, Tepezza was the only FDA-approved drug for thyroid eye disease, pulling in nearly $2 billion a year. Viridian's newly approved Lumvoa just crashed the party, and the implications for patients, pricing, and Amgen's bottom line are bigger than the stock pop suggests.
Kalshi just launched 13 prediction market contracts letting traders bet real money on Phase 3 trial results and FDA approvals. It could reshape how investors price pipeline risk, or it could be a magnet for insider trading. The experiment is live.
Jennifer Doudna's team used AI to design gene-editing enzymes that don't exist in nature, and they work in human cells. The implications for CRISPR's future (and its messy patent landscape) could be enormous.
The FDA just hit 25 telehealth companies with warning letters for marketing compounded knockoffs of Ozempic and Mounjaro with bogus claims. It's the third enforcement wave in under a year, with over 100 total letters sent, and the real numbers on patient harm are alarming.
The European Commission accused Sanofi of running a smear campaign against a rival flu vaccine, and it could change how every pharma company in Europe markets its products. Sanofi is already offering to play nice, but the implications go far beyond one company.
Novartis dropped $1.1 billion upfront on a UK biotech whose lead drugs have never been tested in humans. The bet: a completely new class of ADC payload that could rewrite the rules of cancer treatment, or become pharma's most expensive preclinical flameout.
AbbVie is spending $10.9 billion to acquire Apogee Therapeutics, its biggest deal in five years, betting on a single molecule that could reshape the atopic dermatitis and asthma markets. Wall Street is surprisingly on board, but the payoff won't arrive until 2032.
Sobi's gout therapy NASP nailed its clinical trials, but the FDA blocked approval over manufacturing deficiencies. It's the latest example of a striking trend: roughly 74% of FDA rejection letters now cite factory problems, not failed science.
Pfizer just recalled the only FDA-approved drug that can stop syphilis from passing to unborn babies, and there's no real substitute for pregnant patients. With congenital syphilis already at its highest levels in decades, the timing couldn't be worse.
Sun Pharma just got approval to sell generic Ozempic in South Africa, making it only the second country in the world with a cheaper semaglutide alternative. It's a small market, but it could be the first domino in GLP-1 commoditization across emerging economies.
J&J killed its second eye gene therapy program in a year after PARASOL trial data fell flat. The eye was supposed to be gene therapy's easiest target, so why does the field keep striking out?
The FDA just approved the first-ever regulatory T-cell therapy, and it's not even close to a marginal improvement. Orca Bio's Tregzi doubled chronic GVHD-free survival in transplant patients, creating a whole new category of immunotherapy that has 29 other companies watching very carefully.
Sarepta's Duchenne gene therapy Elevidys just got the FDA's most severe safety warning after fatal liver failures, while the company slashes 36% of its workforce and pivots away from gene therapy entirely. It's a brutal week that raises big questions about the future of the entire field.
The European Commission just approved the first oral GLP-1 weight-loss pill, making Novo Nordisk's Wegovy tablet available across the EU. It could unlock treatment for millions of patients who refused to pick up a needle.
Congo just started testing Gilead's oral antiviral obeldesivir as post-exposure prevention during an active Bundibugyo Ebola outbreak that has killed over 700 people. With no approved treatments for this Ebola species, the trial could reshape how the world fights outbreaks.
Insilico Medicine and Bora Pharmaceuticals just announced a potential $2.5 billion AI alliance, but it's not about discovering drugs. It's about completely rethinking how they're manufactured. Welcome to AI's next frontier in pharma.
Join thousands of biotech professionals who start their day with our free, daily briefing.